{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:24:46Z","timestamp":1793413486976,"version":"4.5.0"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Georgetown University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder that is characterized by amyloid-beta (A\u03b2) accumulation and neuroinflammation. A previous multicenter, phase 2, double-blind, placebo-controlled trial randomized 179 participants into placebo or resveratrol over 52 weeks. Sub-analysis of CSF biomarkers of neuronal damage, inflammation, and microglial activity was performed in a subset of patients treated with a placebo (n = 21) versus resveratrol (n = 30). Markers of neuronal damage, including neuron-specific enolase and hyperphosphorylated neurofilaments, were reduced. Microglial activation was measured via a triggering receptor expressed on myeloid cells (TREM)-2 at baseline and after resveratrol treatment. Resveratrol significantly reduced CSF TREM2 levels and decreased inflammation and tissue damage, including matrix metalloprotease (MMP)-9. Cathepsin D, a lysosomal marker of autophagy, was reduced in the resveratrol group compared with placebo, while angiogenin, a marker of vascular angiogenesis, was increased. These data suggest that resveratrol may exert anti-inflammatory and neuroprotective effects in AD by reducing CSF TREM2 and other markers of neuronal damage. Further research is needed to assess the significance of these biomarker changes on clinical outcomes in patients with neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ijms26115044","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:58:09Z","timestamp":1747994289000},"page":"5044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"26","author":[{"given":"Xiaoguang","family":"Liu","sequence":"first","affiliation":[{"name":"Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-7307","authenticated-orcid":false,"given":"Sean","family":"Baxley","sequence":"additional","affiliation":[{"name":"Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA"},{"name":"Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaeline","family":"Hebron","sequence":"additional","affiliation":[{"name":"Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-2935","authenticated-orcid":false,"given":"Raymond Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Memory Disorders Program, Department of Neurology, Georgetown University, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7063","authenticated-orcid":false,"given":"Charbel","family":"Moussa","sequence":"additional","affiliation":[{"name":"Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrn.2016.7","article-title":"TREM2 variants: New keys to decipher Alzheimer disease pathogenesis","volume":"17","author":"Colonna","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s12094-021-02770-y","article-title":"Resveratrol as a modulatory of apoptosis and autophagy in cancer therapy","volume":"24","author":"Yang","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yang, X., Jiang, T., Wang, Y., and Guo, L. (2019). The Role and Mechanism of SIRT1 in Resveratrol-regulated Osteoblast Autophagy in Osteoporosis Rats. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-44766-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cbin.11402","article-title":"A review of the chemopreventative and chemotherapeutic properties of the phytochemicals berberine, resveratrol and curcumin, and their influence on cell death via the pathways of apoptosis and autophagy","volume":"44","year":"2020","journal-title":"Cell Biol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2011.07.030","article-title":"Autophagy and aging","volume":"146","author":"Rubinsztein","year":"2011","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ptr.7608","article-title":"Resveratrol reverses TGF-beta1-mediated invasion and metastasis of breast cancer cells via the SIRT3\/AMPK\/autophagy signal axis","volume":"37","author":"Wang","year":"2023","journal-title":"Phytother. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Canto","year":"2009","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lin, F., Zhang, S., Zhu, X., and Lv, Z. (2023). Autophagy-related 7 proteindependent autophagy mediates resveratrol-caused upregulation of mitochondrial biogenesis and steroidogenesis in aged Leydig cell. Mol. Biol. Rep., 51.","DOI":"10.1007\/s11033-023-08935-y"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.17373","article-title":"Dihydro-resveratrol ameliorates NLRP3 inflammasome-mediated neuroinflammation via Bnip3-dependent mitophagy in Alzheimer\u2019s disease","volume":"182","author":"Tao","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wu, D., Zhang, H., Li, F., Liu, S., Wang, Y., Zhang, Z., Wang, J., and Wu, Q. (2024). Resveratrol alleviates acute lung injury in mice by promoting Pink1\/Parkin-related mitophagy and inhibiting NLRP3 inflammasome activation. Biochim. Biophys. Acta Gen. Subj., 1868.","DOI":"10.1016\/j.bbagen.2024.130612"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cen, X., Zhang, M., Zhou, M., Ye, L., and Xia, H. (2021). Mitophagy Regulates Neurodegenerative Diseases. Cells, 10.","DOI":"10.3390\/cells10081876"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2016.06.008","article-title":"Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice","volume":"434","author":"Li","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117890","DOI":"10.1016\/j.lfs.2020.117890","article-title":"Effects of resveratrol on autophagy and the expression of inflammasomes in a placental trophoblast oxidative stress model","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.4103\/1673-5374.274331","article-title":"Autophagy and inflammation in ischemic stroke","volume":"15","author":"Mo","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcp.24903","article-title":"Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy","volume":"230","author":"Chang","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116304","DOI":"10.1016\/j.jep.2023.116304","article-title":"Polydatin protects against atherosclerosis by activating autophagy and inhibiting pyroptosis mediated by the NLRP3 inflammasome","volume":"309","author":"Zhang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","article-title":"Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer\u2019s disease","volume":"14","author":"Moussa","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-94-017-7215-0_9","article-title":"Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects","volume":"867","author":"Isgro","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1212\/WNL.0b013e3181fd62d2","article-title":"GFAP and S100B are biomarkers of traumatic brain injury: An observational cohort study","volume":"75","author":"Vos","year":"2010","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jemermed.2007.11.032","article-title":"The prognostic value of neuron-specific enolase in head trauma patients","volume":"38","author":"Meric","year":"2010","journal-title":"J. Emerg. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10143-008-0148-2","article-title":"Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury","volume":"31","author":"Guzel","year":"2008","journal-title":"Neurosurg. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1515\/CCLM.2009.337","article-title":"Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke","volume":"47","author":"Brea","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10998","DOI":"10.1073\/pnas.88.24.10998","article-title":"Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease","volume":"88","author":"Cataldo","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0896-6273(95)90324-0","article-title":"Gene expression and cellular content of cathepsin D in Alzheimer\u2019s disease brain: Evidence for early up-regulation of the endosomal-lysosomal system","volume":"14","author":"Cataldo","year":"1995","journal-title":"Neuron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.1995.64010443.x","article-title":"Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease","volume":"64","author":"Schwagerl","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.2174\/13816128113199990407","article-title":"Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence","volume":"19","author":"Larrosa","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: The in vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/nyas.13431","article-title":"Resveratrol for Alzheimer\u2019s disease","volume":"1403","author":"Sawda","year":"2017","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9932218","DOI":"10.1155\/2021\/9932218","article-title":"Effects and Mechanisms of Resveratrol on Aging and Age-Related Diseases","volume":"2021","author":"Zhou","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, L.X., Li, C.X., Kakar, M.U., Khan, M.S., Wu, P.F., Amir, R.M., Dai, D.F., Naveed, M., Li, Q.Y., and Saeed, M. (2021). Resveratrol (RV): A pharmacological review and call for further research. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112164"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/aje\/kwh069","article-title":"Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer\u2019s disease: A HuGE gene-disease association review","volume":"159","author":"Ntais","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainresbull.2018.02.014","article-title":"Emerging roles of microglial cathepsins in neurodegenerative disease","volume":"139","author":"Lowry","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1152\/jn.00398.2021","article-title":"Phosphorylated neurofilament heavy chain: A potential diagnostic biomarker in amyotrophic lateral sclerosis","volume":"127","author":"Heckler","year":"2022","journal-title":"J. Neurophysiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-024-07508-8","article-title":"Structural mechanism of angiogenin activation by the ribosome","volume":"630","author":"Loveland","year":"2024","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., and Wang, S. (2023). TREM2: Potential therapeutic targeting of microglia for Alzheimer\u2019s disease. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115218"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2\u2014A key player in microglial biology and Alzheimer disease","volume":"14","author":"Ulland","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_42","first-page":"3876","article-title":"TREM2 in Alzheimer\u2019s disease","volume":"53","author":"Jiang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_43","first-page":"2873","article-title":"TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer\u2019s disease mouse models","volume":"214","author":"Jay","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Murphy, G. (2011). Tissue inhibitors of metalloproteinases. Genome Biol., 12.","DOI":"10.1186\/gb-2011-12-11-233"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cabral-Pacheco, G.A., Garza-Veloz, I., la Rosa, C.C.-D., Ramirez-Acuna, J.M., Perez-Romero, B.A., Guerrero-Rodriguez, J.F., Martinez-Avila, N., and Martinez-Fierro, M.L. (2020). The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249739"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s43856-024-00558-z","article-title":"Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with delirium","volume":"4","author":"Aksnes","year":"2024","journal-title":"Commun. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0024-3205(03)00146-2","article-title":"TIMPs and MMPs expression in CSF from patients with TSP\/HAM","volume":"72","author":"Kettlun","year":"2003","journal-title":"Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/jcbfm.2011.197","article-title":"Neurological diseases in relation to the blood-brain barrier","volume":"32","author":"Rosenberg","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/glia.10108","article-title":"Matrix metalloproteinases in neuroinflammation","volume":"39","author":"Rosenberg","year":"2002","journal-title":"Glia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1089\/neu.2006.0245","article-title":"The mayo classification system for traumatic brain injury severity","volume":"24","author":"Malec","year":"2007","journal-title":"J. Neurotrauma"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ghiam, M.K., Patel, S.D., Hoffer, A., Selman, W.R., Hoffer, B.J., and Hoffer, M.E. (2021). Drug Repurposing in the Treatment of Traumatic Brain Injury. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.635483"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0079-6123(06)61018-2","article-title":"Experimental models of repetitive brain injuries","volume":"161","author":"Weber","year":"2007","journal-title":"Prog. Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11010-006-9253-0","article-title":"Neuroprotection by resveratrol against traumatic brain injury in rats","volume":"294","author":"Ates","year":"2007","journal-title":"Mol. Cell. Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.12659\/MSM.909042","article-title":"Resveratrol Attenuates Cognitive Deficits of Traumatic Brain Injury by Activating p38 Signaling in the Brain","volume":"24","author":"Shi","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_55","first-page":"924","article-title":"Resveratrol Treatment Prevents Hippocampal Neurodegeneration in a Rodent Model of Traumatic Brain Injury","volume":"27","author":"Atalay","year":"2017","journal-title":"Turk. Neurosurg."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rahman, M.H., Akter, R., Bhattacharya, T., Abdel-Daim, M.M., Alkahtani, S., Arafah, M.W., Al-Johani, N.S., Alhoshani, N.M., Alkeraishan, N., and Alhenaky, A. (2020). Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer\u2019s Disease. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.619024"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1074\/jbc.M109.060061","article-title":"AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism","volume":"285","author":"Vingtdeux","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_58","first-page":"676","article-title":"Resveratrol inhibits IL-1\u03b2-induced inflammatory signaling and apoptosis in human articular chondrocytes: Potential for use as a therapeutic agent for osteoarthritis","volume":"77","author":"Shakibaei","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101766","DOI":"10.1016\/j.eclinm.2022.101766","article-title":"Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study","volume":"55","author":"Zamzam","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12640-024-00712-4","article-title":"FABP3 Induces Mitochondrial Autophagy to Promote Neuronal Cell Apoptosis in Brain Ischemia-Reperfusion Injury","volume":"42","author":"Zhong","year":"2024","journal-title":"Neurotox. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/35081564","article-title":"Alpha-synuclein and neurodegenerative diseases","volume":"2","author":"Goedert","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","article-title":"Mitochondria in the aetiology and pathogenesis of Parkinson\u2019s disease","volume":"7","author":"Schapira","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_65","first-page":"S241","article-title":"Is there a pathogenic role for mitochondria in Parkinson\u2019s disease?","volume":"3","author":"Tocilescu","year":"2009","journal-title":"Park. Relat Disord."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.neurol.2013.06.003","article-title":"Mitochondrial dysfunctions in Parkinson\u2019s disease","volume":"170","author":"Gautier","year":"2014","journal-title":"Rev. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.20344\/amp.11978","article-title":"[Parkinson\u2019s Disease: Clinical Review and Update]","volume":"32","author":"Cabreira","year":"2019","journal-title":"Acta Med. Port."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_69","first-page":"382","article-title":"Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease, Nature clinical practice","volume":"2","author":"Olanow","year":"2006","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and Amyotrophic Lateral Sclerosis-An updated review","volume":"71","author":"Alqahtani","year":"2023","journal-title":"Mitochondrion"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mahadevan, H.M., Hashemiaghdam, A., Ashrafi, G., and Harbauer, A.B. (2021). Mitochondria in Neuronal Health: From Energy Metabolism to Parkinson\u2019s Disease. Adv. Biol., 5.","DOI":"10.1002\/adbi.202100663"},{"key":"ref_72","first-page":"615","article-title":"Mitochondria-mediated damage to dopaminergic neurons in Parkinson\u2019s disease","volume":"41","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.neuroscience.2014.10.037","article-title":"Dopamine midbrain neurons in health and Parkinson\u2019s disease: Emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels","volume":"284","author":"Dragicevic","year":"2015","journal-title":"Neuroscience"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jnc.15154","article-title":"The multi-faceted role of mitochondria in the pathology of Parkinson\u2019s disease","volume":"156","author":"Trinh","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Mischley, L.K., Shankland, E., Liu, S.Z., Bhayana, S., Fox, D.J., and Marcinek, D.J. (2023). ATP and NAD+ Deficiency in Parkinson\u2019s Disease. Nutrients, 15.","DOI":"10.3390\/nu15040943"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.neurol.2023.08.011","article-title":"Importance of glucose and its metabolism in neurodegenerative disorder, as well as the combination of multiple therapeutic strategies targeting alpha-synuclein and neuroprotection in the treatment of Parkinson\u2019s disease","volume":"180","author":"Siddique","year":"2024","journal-title":"Rev. Neurol."},{"key":"ref_77","first-page":"1237","article-title":"Exposure to Glycolysis-Enhancing Drugs and Risk of Parkinson\u2019s Disease: A Meta-Analysis","volume":"14","author":"Ribeiro","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2021.11.022","article-title":"A pilot to assess target engagement of terazosin in Parkinson\u2019s disease","volume":"94","author":"Schultz","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, L., Voullaire, L., Sandi, C., Pook, M.A., Ioannou, P.A., Delatycki, M.B., and Sarsero, J.P. (2013). Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055940"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu","year":"2015","journal-title":"J. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11011-012-9302-1","article-title":"Mucopolysaccharidosis type I: Current knowledge on its pathophysiological mechanisms","volume":"27","author":"Campos","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, and VI: Brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2013.10.005","article-title":"Structural and clinical implications of amino acid substitutions in alpha-L-iduronidase: Insight into the basis of mucopolysaccharidosis type I","volume":"111","author":"Saito","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rintz, E., Ziemian, M., Kobus, B., Gaffke, L., Pierzynowska, K., and Wegrzyn, G. (2024). Synergistic effects of resveratrol and enzyme replacement therapy in the Mucopolysaccharidosis type I. Biochem. Pharmacol., 229.","DOI":"10.1016\/j.bcp.2024.116467"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.biopha.2018.11.075","article-title":"Resveratrol: From enhanced biosynthesis and bioavailability to multitargeting chronic diseases","volume":"109","author":"Pannu","year":"2019","journal-title":"Biomed. Pharmacother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:22Z","timestamp":1760031562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115044"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115044","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}